Table 3.

TEAEs by SOC and PT

TEAEs (any TEAE ≥2.5% in any treatment group)—n (%)	Brodalumab 210 mg N=80	Placebo N=79
Infections and infestations	18 (22.5)	15 (19.0)
Nasopharyngitis	8 (10.0)	9 (11.4)
Rhinitis	3 (3.8)	1 (1.3)
Upper respiratory tract infection	2 (2.5)	5 (6.3)
Gastrointestinal disorders	13 (16.3)	7 (8.9)
Diarrhoea	3 (3.8)	1 (1.3)
Mouth ulceration	3 (3.8)	1 (1.3)
Abdominal pain upper	2 (2.5)	0
Vomiting	2 (2.5)	0
Investigations	7 (8.8)	1 (1.3)
Alanine aminotransferase increased	4 (5.0)	1 (1.3)
Aspartate aminotransferase increased	4 (5.0)	1 (1.3)
Liver function test abnormal	2 (2.5)	0
Musculoskeletal and connective tissue disorders	6 (7.5)	6 (7.6)
Back pain	0	2 (2.5)
Injury, poisoning and procedural complications	5 (6.3)	6 (7.6)
Ligament sprain	1 (1.3)	2 (2.5)
Metabolism and nutrition disorders	4 (5.0)	2 (2.5)
Nervous system disorders	3 (3.8)	2 (2.5)
Skin and subcutaneous tissue disorders	3 (3.8)	5 (6.3)
Pruritus	2 (2.5)	1 (1.3)
General disorders and administration site conditions	2 (2.5)	6 (7.6)
Fatigue	1 (1.3)	2 (2.5)
Respiratory, thoracic and mediastinal disorders	2 (2.5)	3 (3.8)
Vascular disorders	2 (2.5)	2 (2.5)
Hypertension	2 (2.5)	2 (2.5)

PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event.